Breaking News, Financial News

Financial Report: Gilead 3Q

Revenues up 15% in the quarter

Gilead

3Q Revenues: $2.8 billion (+15%)

3Q Earnings: $785.2 million (+17%)

YTD Revenues: $8.1 billion (+14%)

YTD Earnings: $2.3 billion (+25%)

Comments: Product sales for the quarter increased 20% in the U.S. and 5% in Europe. Antiviral product sales increased 14% to $2.3 billion driven by strong growth in the new single tablet regimen products, Stribild (+722% to $144 million) and Complera/Eviplera (+112% to $210.7 million). Cardiovascular product sales were up 25% to $250.9 million with Letairis sales up 29% to $135.1 million. Ranexa sales were up 22% to $115.8 million.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters